ORIC Pharmaceuticals
ORIC · Nasdaq · United States
Share price · ORIC
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ORIC's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 26 Oct 2026-32.0%
- 4 Aug 2026+27.1%
- 24 Jul 2026+11.1%
Nothing announced by ORIC that day or the session before.
- 2 Apr 2026+18.9%
Nothing announced by ORIC that day or the session before.
- 1 Apr 2026-41.0%
- 9 Mar 2026-15.0%
- 24 Feb 2026+14.6%
- 28 Jan 2026-9.3%
Nothing announced by ORIC that day or the session before.
- 14 Jan 2026+10.9%
Nothing announced by ORIC that day or the session before.
- 13 Jan 2026+10.8%
Share of unusual movement by asset
For each asset, the share of ORIC's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | EED (PRC2)Small molecule | Prostate Cancer | |
| Phase 1/2 | EGFR/HER2Small molecule | Non-Small Cell Lung Cancer | |
| Phase 1 | CD73Small molecule | Multiple Myeloma |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $36M | $38M+ $227M short-term inv. | $41M-$32M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | — | $31M | $57M+ $226M short-term inv. | $36M-$32M operating cash flow | report ↗ |
| 2025-Q3 | — | $29M | $50M+ $237M short-term inv. | $33M-$25M operating cash flow | report ↗ |
| 2025-Q2 | — | $31M | $76M+ $207M short-term inv. | $36M-$31M operating cash flow | report ↗ |
| 2025-Q1 | — | $25M | $50M+ $154M short-term inv. | $30M-$33M operating cash flow | report ↗ |
| 2024-Q3 | — | $31M | $45M+ $228M short-term inv. | $35M-$29M operating cash flow | report ↗ |
| 2024-Q2 | — | $29M | $50M+ $237M short-term inv. | $32M-$26M operating cash flow | report ↗ |
| 2024-Q1 | — | $22M | $57M+ $260M short-term inv. | $25M-$30M operating cash flow | report ↗ |
| 2023-Q3 | — | $22M | $27M+ $201M short-term inv. | $25M-$20M operating cash flow | report ↗ |
| 2023-Q2 | — | $19M | $104M+ $160M short-term inv. | $23M-$21M operating cash flow | report ↗ |
| 2023-Q1 | — | $20M | $59M+ $131M short-term inv. | $24M-$21M operating cash flow | report ↗ |
| 2022-Q3 | — | $15M | $30M+ $165M short-term inv. | $25M-$19M operating cash flow | report ↗ |
| 2022-Q2 | — | $14M | $50M+ $178M short-term inv. | $20M-$18M operating cash flow | report ↗ |
| 2022-Q1 | — | $17M | $113M+ $122M short-term inv. | $23M-$23M operating cash flow | report ↗ |
| 2021-Q3 | — | $13M | $242M+ $48M short-term inv. | $18M-$12M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $110M | $46M+ $236M short-term inv. | $32M-$111M operating cash flow | report ↗ |
For fiscal year 2025, ORIC Pharmaceuticals did not disclose revenue. R&D expenses were $109.8 million, down 3.7% YoY from $114.1 million, while cash, cash equivalents and investments totaled $392.3 million as of December 31, 2025. The company reported a net loss of $129.47 million for the year.
ORIC guided that its cash and investments are expected to fund operations into 2H 2028, and it raised $264 million from healthcare specialist funds during the year. Clinical highlights included rinzimetostat Phase 1b data in mCRPC showing PSA and ctDNA responses, with provisional recommended Phase 2 doses selected and dose optimization initiated with AR inhibitors, and enozertinib Phase 1b data in EGFR exon 20 and PACC-mutant NSCLC showing systemic and intracranial activity, with a Phase 3 monotherapy dose selected and a collaboration with Johnson & Johnson to evaluate combination with SC amivantamab. The company expects multiple clinical data readouts in 2026 and plans to initiate its first global Phase 3 registrational trial for rinzimetostat in 1H 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $114M | $60M+ $197M short-term inv. | $32M-$113M operating cash flow | report ↗ |
| 2023-FY | — | $85M | $24M+ $185M short-term inv. | $25M-$86M operating cash flow | report ↗ |
| 2022-FY | — | $62M | $67M+ $139M short-term inv. | $22M-$75M operating cash flow | report ↗ |
| 2021-FY | — | $57M | $226M+ $11M short-term inv. | $20M-$60M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 16 sales ($3.0M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-20 | Piscitelli Dominic · Chief Financial Officer | Option exercise | 14,000 | $4.36 | $61K | Form 4 |
| 2026-10-20 | Piscitelli Dominic · Chief Financial Officer | Open-market sale | 14,000 | $13.53 | $189K | Form 4 |
| 2026-10-20 | Piscitelli Dominic · Chief Financial Officer | Option exercise (derivative) | 14,000 | — | — | Form 4 |
| 2026-10-01 | Heyman Richard A. · director | Option exercise | 3,500 | $1.60 | $6K | Form 4 |
| 2026-10-01 | Heyman Richard A. · director | Open-market sale | 3,500 | $12.91 | $45K | Form 4 |
| 2026-10-01 | Heyman Richard A. · director | Open-market sale | 3,200 | $12.91 | $41K | Form 4 |
| 2026-10-01 | Heyman Richard A. · director | Option exercise (derivative) | 3,500 | — | — | Form 4 |
| 2026-09-28 | Piscitelli Dominic · Chief Financial Officer | Option exercise | 13,400 | $4.36 | $58K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 182 reporting institutions held 119.4M shares ($1.4B, 115.2% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Nextech Invest, Ltd. | 7,162,637 | $90.8M |
| 2 | EcoR1 Capital, LLC | 6,728,116 | $85.2M |
| 3 | BlackRock, Inc. | 5,984,552 | $75.8M |
| 4 | VIKING GLOBAL INVESTORS LP | 5,824,533 | $73.8M |
| 5 | SR One Capital Management, LP | 4,514,929 | $58.5M |
| 6 | Pfizer Inc | 4,780,401 | $57.7M |
| 7 | ALKEON CAPITAL MANAGEMENT LLC | 4,504,096 | $57.1M |
| 8 | Venrock Adviser, LLC | 4,319,765 | $54.7M |
| 9 | NEA Management Company, LLC | 4,118,621 | $52.2M |
| 10 | STATE STREET CORP | 3,702,196 | $46.9M |
| 11 | VANGUARD CAPITAL MANAGEMENT LLC | 3,687,007 | $46.7M |
| 12 | Column Group LLC | 3,540,777 | $44.9M |
| 13 | Siren, L.L.C. | 2,998,192 | $38.0M |
| 14 | ORBIMED ADVISORS LLC | 2,693,929 | $34.1M |
| 15 | AIHC Capital Management Ltd | 2,459,551 | $31.2M |